[144] Avidity Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Avidity Biosciences, Inc. (RNA) reported a proposed sale under Rule 144 of 45,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,073,150.00. The filing indicates the shares were acquired and are to be sold on 08/15/2025 following the exercise of stock options granted by the issuer, with payment made in cash. The company has 128,653,337 shares outstanding, and the filer reports no other sales in the past three months. The filer certifies they are not aware of undisclosed material adverse information and follows the Rule 144 attestation requirements.

Insights

Securities Analyst

TL;DR Routine disposition after option exercise; size is immaterial relative to outstanding shares.

The filing shows a sale of 45,000 shares executed the same day as an option exercise and routed through Morgan Stanley Smith Barney LLC. At an aggregate value of $2.07 million versus 128.65 million shares outstanding, this represents approximately 0.035% of the float, which is immaterial for market impact. No prior sales in the last three months are reported, reducing concerns about a patterned divestiture. The submission includes the required Rule 144 attestation about material nonpublic information.

Corporate Governance Expert

TL;DR Compliance-focused filing reflecting exercise-and-sell of option proceeds; governance disclosure appears standard.

The record lists acquisition by exercise of stock options and immediate cash sale, a common liquidity event for option holders. The filer affirms no undisclosed material adverse information, satisfying the attestation expectation for Rule 144 notices. The absence of other sales in the prior three months and the explicit exercise date provide clear traceability for compliance reviews. No governance red flags are apparent from the data provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45000	2073150.00	128653337	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Exercise of Stock Options	Issuer			45000	08/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Avidity Biosciences (RNA) file in this Form 144?

The filing notifies a proposed sale of 45,000 common shares acquired by exercise of stock options and to be sold on 08/15/2025 through Morgan Stanley Smith Barney LLC.

How much are the shares worth in the Form 144 filing for RNA?

The aggregate market value reported is $2,073,150.00 for the 45,000 shares to be sold.

How many Avidity Biosciences shares are outstanding according to the filing?

The filing states there are 128,653,337 shares outstanding.

Was the acquisition of the shares a gift or purchase in the RNA Form 144?

The shares were acquired on 08/15/2025 by exercise of stock options; payment was made in cash; it was not reported as a gift.

Did the filer report other sales in the past three months in the Form 144?

The filing reports Nothing to Report for securities sold during the past three months.